Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
December 25, 2024
December 25, 2024
PALO ALTO, California, Dec. 25 -- Cooley, a law firm, issued the following news release:
San Diego - December 23, 2024 - Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
The transaction is expected to close in mid-2025, subject to customary closing conditions, including . . .
San Diego - December 23, 2024 - Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).
The transaction is expected to close in mid-2025, subject to customary closing conditions, including . . .